These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 31365579)

  • 1. Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
    Brogna C; Coratt G; Pane M; Ricotti V; Messina S; D'Amico A; Bruno C; Vita G; Berardinelli A; Mazzone E; Magri F; Ricci F; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Previtali SC; Politano L; Comi GP; Sansone VA; Donati A; Bertini E; Muntoni F; Goemans N; Mercuri E;
    PLoS One; 2019; 14(7):e0220714. PubMed ID: 31365579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.
    Boca SM; Nishida M; Harris M; Rao S; Cheema AK; Gill K; Wang D; An L; Gauba R; Seol H; Morgenroth LP; Henricson E; McDonald C; Mah JK; Clemens PR; Hoffman EP; Hathout Y; Madhavan S
    PLoS One; 2016; 11(7):e0159895. PubMed ID: 27434074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy.
    PLOS ONE Staff
    PLoS One; 2019; 14(2):e0212820. PubMed ID: 30785959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.
    Brinkmeyer-Langford C; Chu C; Balog-Alvarez C; Yu X; Cai JJ; Nabity M; Kornegay JN
    PLoS One; 2020; 15(7):e0236916. PubMed ID: 32702009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy.
    Cao L; Han G; Gu B; Yin H
    PLoS One; 2018; 13(11):e0207817. PubMed ID: 30440030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction: Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.
    PLOS ONE Staff
    PLoS One; 2015; 10(3):e0121882. PubMed ID: 25806823
    [No Abstract]   [Full Text] [Related]  

  • 8. Correction: Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes.
    Pane M; Mazzone ES; Sivo S; Sormani MP; Messina S; D'Amico A; Carlesi A; Vita G; Fanelli L; Berardinelli A; Torrente Y; Lanzillotta V; Viggiano E; D'Ambrosio P; Cavallaro F; Frosini S; Barp A; Bonfiglio S; Scalise R; De Sanctis R; Rolle E; Graziano A; Magri F; Palermo C; Rossi F; Donati MA; Sacchini M; Arnoldi MT; Baranello G; Mongini T; Pini A; Battini R; Pegoraro E; Previtali S; Bruno C; Politano L; Comi GP; Bertini E; Mercuri E
    PLoS One; 2015; 10(12):e0144079. PubMed ID: 26636671
    [No Abstract]   [Full Text] [Related]  

  • 9. Correction: Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
    Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
    PLoS One; 2020; 15(10):e0241430. PubMed ID: 33091069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/IIa Clinical Trial in Duchenne Muscular Dystrophy Using Systemically Delivered Morpholino Antisense Oligomer to Skip Exon 53 (SKIP-NMD).
    Hum Gene Ther Clin Dev; 2015 Jun; 26(2):92-5. PubMed ID: 26086759
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
    Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
    Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy.
    Wary C; Azzabou N; Giraudeau C; Le Louër J; Montus M; Voit T; Servais L; Carlier P
    NMR Biomed; 2015 Sep; 28(9):1150-62. PubMed ID: 26215733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History.
    Kinane TB; Mayer OH; Duda PW; Lowes LP; Moody SL; Mendell JR
    J Neuromuscul Dis; 2018; 5(1):47-58. PubMed ID: 29278896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased cerebral perfusion in Duchenne muscular dystrophy patients.
    Doorenweerd N; Dumas EM; Ghariq E; Schmid S; Straathof CS; Roest AA; Wokke BH; van Zwet EW; Webb AG; Hendriksen JG; van Buchem MA; Verschuuren JJ; Asllani I; Niks EH; van Osch MJ; Kan HE
    Neuromuscul Disord; 2017 Jan; 27(1):29-37. PubMed ID: 27927595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment.
    Le Moing AG; Seferian AM; Moraux A; Annoussamy M; Dorveaux E; Gasnier E; Hogrel JY; Voit T; Vissière D; Servais L
    PLoS One; 2016; 11(6):e0156696. PubMed ID: 27271157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial.
    Seferian AM; Moraux A; Annoussamy M; Canal A; Decostre V; Diebate O; Le Moing AG; Gidaro T; Deconinck N; Van Parys F; Vereecke W; Wittevrongel S; Mayer M; Maincent K; Desguerre I; Thémar-Noël C; Cuisset JM; Tiffreau V; Denis S; Jousten V; Quijano-Roy S; Voit T; Hogrel JY; Servais L
    PLoS One; 2015; 10(2):e0113999. PubMed ID: 25643053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with Duchenne muscular dystrophy are significantly shorter than those with Becker muscular dystrophy, with the higher incidence of short stature in Dp71 mutated subgroup.
    Matsumoto M; Awano H; Lee T; Takeshima Y; Matsuo M; Iijima K
    Neuromuscul Disord; 2017 Nov; 27(11):1023-1028. PubMed ID: 28734761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viltolarsen for the treatment of Duchenne muscular dystrophy.
    Roshmi RR; Yokota T
    Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Steroid Therapy in Duchenne Muscular Dystrophy-Positive Results versus Side Effects.
    Schara U; Mortier ; Mortier W
    J Clin Neuromuscul Dis; 2001 Jun; 2(4):179-83. PubMed ID: 19078632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.